Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Corporate Presentation

Updated as of October, 2018

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.

Research

At Oasmia, we’re developing the next generation of drugs with focus on oncology.

Production

At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share

News

New Board starts reviewing the situation in Oasmia

March 19th, the Extra General Meeting in Oasmia elected a new Board on the initiative of the main owner Arwidsro. The EGM was well represented with over a hundred participating shareholders and over 4...
Read more

Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019

In Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) an extraordinary general meeting was held today. The extraordinary general meeting was convened at the request of shareholders re...
Read more

Oasmia announces a prospectus regarding admission to trading of new shares

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) has prepared a prospectus regarding the admission to trading of the 22,948,535 shares in the Company that were issued in the directe...
Read more
To news archive